Skip to main content
SpringerLink
Log in

Neue Daten zur Behandlung uroonkologischer Patienten

Update Uroonkologie 2022

New data on the treatment of patients in uro-oncology

Uro-oncology update 2022

  • Update Onkologie
  • Published:
Der Onkologe Aims and scope

Zusammenfassung

Die Behandlung uroonkologischer Erkrankungen wird zunehmend individueller und damit auch komplexer. Neue Daten zur Systemtherapie urothelialer Karzinome, des Prostata- und des Nierenzellkarzinoms, aber auch zu operativen und strahlentherapeutischen Optionen beim Keimzelltumor des Mannes sowie zu nuklearmedizinischen Behandlungsoptionen des metastasierten Prostatakarzinoms bereichern das therapeutische Spektrum in der Uroonkologie allgemein. Dies fördert auf der einen Seite eine zunehmende Interdisziplinarität in der Versorgung der Patienten und auf der anderen Seite eine zunehmende Spezialisierung auf uroonkologische Krankheitsbilder auf der Seite der Behandler. Diese Übersicht fasst die wichtigsten Daten zu uroonkologischen Erkrankungen des letzten Jahres zusammen und gibt einen Überblick ihrer Bedeutung für den klinischen Alltag.

Abstract

Treatment of uro-oncological diseases is becoming increasingly individualized and thus also more complex. New data on systemic treatment of urothelial carcinomas, prostate and renal cell carcinoma, but also on surgical and radiotherapeutic options for germ cell tumors in men as well as on nuclear medicine treatment options for metastatic prostate carcinoma are broadening the therapeutic spectrum in uro-oncology in general. On the one hand, this promotes an increasing interdisciplinarity in the care of patients and on the other hand, this requires an increasing specialization of the individual health care providers. In this article, the most important data on uro-oncological diseases of the last year are summarized and an overview of their significance for daily clinical practice is provided.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Apolo AB, Powles T, Burotto M et al (2021) Nivolumab plus cabozantinib (N+C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial. J Clin Oncol 39(15_suppl):4553

    Article  Google Scholar 

  2. Armstrong AJ, Szmulewitz RZ, Petrylak DP et al (2019) ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol 37:2974–2986

    Article  CAS  Google Scholar 

  3. Bajorin DF, Witjes JA, Gschwend JE et al (2021) Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med 384:2102–2114

    Article  CAS  Google Scholar 

  4. Canter D, Viterbo R, Kutikov A et al (2011) Baseline renal function status limits patient eligibility to receive perioperative chemotherapy for invasive bladder cancer and is minimally affected by radical cystectomy. Urology 77:160–165

    Article  Google Scholar 

  5. Chi KN, Agarwal N, Bjartell A et al (2019) Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 381:13–24

    Article  CAS  Google Scholar 

  6. Choueiri TK, Tomczak P, Park SH et al (2021) Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: randomized, double-blind, phase III KEYNOTE-564 study. J Clin Oncol 39(18_suppl):LBA5

    Article  Google Scholar 

  7. Dash A, Galsky MD, Vickers AJ et al (2006) Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 107:506–513

    Article  CAS  Google Scholar 

  8. Davis ID, Martin AJ, Stockler MR et al (2019) Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med 381:121–131

    Article  CAS  Google Scholar 

  9. Fizazi K, Carles-Galceran J, Foulon S et al (2021) A phase III trial with a 2x2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: overall survival with abiraterone acetate plus prednisone in PEACE‑1. Ann Oncol 32(suppl_5):S1283–S1346. https://doi.org/10.1016/annonc/annonc741

    Article  Google Scholar 

  10. Fizazi K, Tran N, Fein L et al (2017) Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 377:352–360

    Article  CAS  Google Scholar 

  11. Hellesnes R, Myklebust TA, Fossa SD et al (2021) Testicular cancer in the cisplatin era: causes of death and mortality rates in a population-based cohort. J Clin Oncol 39:3561–3573

    Article  CAS  Google Scholar 

  12. Hofman MS, Emmett L, Sandhu SK et al (2020) TheraP: a randomised phase II trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: initial results (ANZUP protocol 1603). J Clin Oncol 38(15_suppl):5500

    Article  Google Scholar 

  13. Hussain M, Mateo J, Fizazi K et al (2020) Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med 383:2345–2357

    Article  CAS  Google Scholar 

  14. James ND, Sydes MR, Clarke NW et al (2016) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387:1163–1177

    Article  CAS  Google Scholar 

  15. Kyriakopoulos CE, Chen YH, Carducci MA et al (2018) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol 36:1080–1087

    Article  CAS  Google Scholar 

  16. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF) (2020) S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms, Langversion 2.0. www.leitlinienprogramm-onkologie.de/leitlinien/harnblasenkarzinom (AWMF-Registrierungsnummer 032/038OL). Zugegriffen: 05. Januar 2021

  17. McDermott DF, Choueiri TK, Bauer TM et al (2021) Phase II study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, plus cabozantinib for treatment of advanced clear cell renal cell carcinoma (ccRCC). Ann Oncol 32(suppl_5):S678–S724. https://doi.org/10.1016/annonc/annonc675

    Article  Google Scholar 

  18. Motzer R, Alekseev B, Rha SY et al (2021) Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 384:1289–1300

    Article  CAS  Google Scholar 

  19. Necchi A, Anichini A, Raggi D et al (2018) Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study. J Clin Oncol 36:3353–3360

    Article  CAS  Google Scholar 

  20. Powles T, Kockx M, Rodriguez-Vida A et al (2019) Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat Med 25:1706–1714

    Article  CAS  Google Scholar 

  21. Powles T, Park SH, Voog E et al (2020) Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med 383:1218–1230

    Article  CAS  Google Scholar 

  22. Powles T, Rosenberg JE, Sonpavde GP et al (2021) Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med 384:1125–1135

    Article  CAS  Google Scholar 

  23. Rosenberg JE, O’Donnell PH, Balar AV et al (2019) Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. J Clin Oncol 37:2592–2600

    Article  CAS  Google Scholar 

  24. Sartor AO, Morris MJ, Messman R et al (2020) VISION: an international, prospective, open-label, multicenter, randomized phase III study of 177Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 38(6_suppl):TPS5099

    Article  Google Scholar 

  25. Thompson RH, Boorjian SA, Kim SP et al (2014) Eligibility for neoadjuvant/adjuvant cisplatin-based chemotherapy among radical cystectomy patients. BJU Int 113:E17–E21

    Article  CAS  Google Scholar 

  26. Trabert B, Chen J, Devesa SS et al (2015) International patterns and trends in testicular cancer incidence, overall and by histologic subtype, 1973–2007. Andrology 3:4–12

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Urologie, Medizinische Fakultät und Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität, Moorenstr. 5, 40225, Düsseldorf, Deutschland

    G. Niegisch

Authors
  1. C. Grunewald
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Y. Che
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Lakes
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Rehlinghaus
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. Albers
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Niegisch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. Niegisch.

Ethics declarations

Interessenkonflikt

M. Rehlinghaus: Advisory Board, Beratungen: Merck Serono. G. Niegisch: Vorträge, Symposien: – Roche Pharma, MEDAC, Pfizer, BMS, AstraZeneca; Advisory Board, Beratungen – Roche Pharma, Sanofi, BMS, Merck Serono, Pfizer, MEDAC, Ipsen, Janssen; Reisekosten, Kongressgebühren – Roche Pharma, Pfizer, Merck. C. Grunewald, Y. Che, J. Lakes und P. Albers geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Grunewald, C., Che, Y., Lakes, J. et al. Neue Daten zur Behandlung uroonkologischer Patienten. Onkologe 28, 429–435 (2022). https://doi.org/10.1007/s00761-022-01109-8

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-022-01109-8

Schlüsselwörter

Keywords

Search

Navigation